Glioblastoma causes pain in most patients at some point during the disease, but not always in the way people expect. Headache is the symptom most closely associated with brain tumors, yet it is the first noticeable sign in only a minority of glioma patients and often feels unremarkable when it does appear. The more intense and varied pain tends to come later, driven by rising pressure inside the skull, nerve damage from the tumor or its treatment, and secondary complications like muscle spasticity and seizures. Understanding the full landscape of glioblastoma-related pain means looking well beyond the headache.
How Common Are Headaches in Glioblastoma
The popular image of a brain tumor headache as an early, dramatic warning sign is mostly wrong. In a large cross-sectional study of glioma patients, only about 12.5% reported headache as the symptom that brought them to a doctor, and nearly half of those headaches resembled ordinary tension-type headaches rather than anything distinctly alarming.1PubMed. Headache as a presenting symptom of glioma: A cross-sectional study A separate prospective study of patients with various intracranial tumors found a higher overall headache prevalence of roughly 48%, but even then, the headache was described as nonspecific and difficult to distinguish from common primary headaches.2PubMed. Headache attributed to intracranial tumours: a prospective cohort study Registry data from Denmark confirmed that headache alone is a rare first symptom of glioma, and when it does appear alongside a high-grade tumor, it often shows up less than a month before diagnosis, suggesting rapid growth rather than a slow buildup.3PubMed. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry
The gap between those numbers matters. Whether a given patient has headache at presentation depends on where the tumor sits, how fast it is growing, and whether it is already blocking the flow of cerebrospinal fluid. Tumors near the base of the skull or in the back of the brain are more likely to cause headache early because they interfere with fluid drainage more readily.4PubMed. Headache in intracranial tumors A tumor in the frontal lobe, by contrast, can grow to a considerable size before producing any pain at all, often showing up first as personality changes or cognitive slowing that neither the patient nor their family initially connects to a brain tumor.
What a Glioblastoma Headache Actually Feels Like
There is a textbook description of brain tumor headache that gets repeated constantly: worst in the morning, worse when lying down, aggravated by straining or coughing, and accompanied by nausea and vomiting. That description exists for a reason, but research over the past few decades has shown that this “classic” presentation is actually uncommon, especially early in the disease.5PubMed. Update on headache and brain tumors Most patients with a tumor-related headache describe something that feels like a dull, pressing pain, similar to what anyone might call a tension headache. It is typically on one side or worse on the side where the tumor sits, and it tends to grow more persistent and harder to relieve over weeks.
The morning-worsening pattern does develop in some patients, and when it does, it reflects a real physiological process. When you lie flat for several hours, the normal mechanisms that keep intracranial pressure in check work less efficiently, and any existing swelling from the tumor pushes harder against pain-sensitive structures. That said, many glioblastoma patients with headache never notice a clear morning peak. The headache simply becomes more constant and less responsive to over-the-counter painkillers over time, which is actually the more useful red flag than any specific pattern tied to time of day.
Why the Tumor Hurts When the Brain Itself Cannot Feel Pain
Brain tissue has no pain receptors. You could poke the cortex with a needle and a conscious patient would not feel it, a fact that neurosurgeons rely on during awake craniotomies. The pain from a glioblastoma does not come from the brain tissue the tumor is invading. It comes from the structures around and within the brain that do have pain-sensing nerve fibers: the meninges (the layered membranes wrapping the brain), blood vessels on the brain’s surface, and certain cranial nerves.
Glioblastomas generate pain through several overlapping mechanisms. The growing mass pushes on or stretches those pain-sensitive structures, a process called traction. The tumor also causes swelling in surrounding brain tissue, which raises the overall pressure inside the skull.6PubMed Central. A Biomechanical Model of Tumor-Induced Intracranial Pressure and Edema in Brain Tissue Sometimes the tumor bleeds internally or blocks the pathways through which cerebrospinal fluid drains, causing a rapid spike in pressure that produces sudden, severe headache alongside nausea or visual disturbances. One study found that the progressive worsening of headache correlated closely with the degree of swelling around the tumor rather than the size of the tumor itself, which helps explain why a relatively small glioblastoma in the wrong spot can cause more pain than a larger one elsewhere.4PubMed. Headache in intracranial tumors
Pain Beyond Headache
Headache gets most of the attention, but glioblastoma can generate pain throughout the body. Studies estimate that roughly 13% to 25% of brain tumor patients experience bodily pain separate from their headache, and managing it requires the same stepwise approach used for pain in other advanced cancers.7Neuro-Oncology. Palliative care and end-of-life care in adults with malignant brain tumors
Some of that body pain is neuropathic, meaning the tumor damages nerve pathways inside the brain in a way that produces burning, shooting, or electric-shock sensations in the limbs or trunk even though there is nothing wrong with the body part that hurts. One documented case involved an eighteen-year-old with a grade IV diffuse glioma who developed severe central neuropathic pain that did not respond to standard nerve-pain medications and ultimately required a combination of high-dose gabapentin, methadone, and oxycodone to achieve any meaningful relief.8PubMed. Intractable Central Pain in a Patient With Diffuse Glioma This kind of pain is particularly difficult to treat because it originates from faulty signaling in the central nervous system rather than from inflammation or tissue damage at the site where the pain is felt.
Another source of pain in advanced glioblastoma is spasticity. As the tumor or its treatment damages motor pathways, muscles can develop abnormally high tone, meaning they contract involuntarily and resist being moved. A case report described a patient whose limbs would bend or extend in response to any stimulation, producing pain described as excruciating.9PubMed Central. Botulinum Therapy for Pain Caused by Spasticity in Advanced Stages of Brain Tumor in Adolescents: A Case Report Spasticity-related pain tends to appear in recurrent or late-stage disease and adds a physical dimension that complicates caregiving, positioning, and sleep.
Pain Caused by Treatment
Glioblastoma treatment itself is a significant source of pain, and patients sometimes struggle to distinguish treatment-related pain from tumor-related pain.
Craniotomy, the surgical opening of the skull to remove as much tumor as possible, reliably produces postoperative headache. This pain is well-documented and can be accompanied by nausea, vomiting, and blood pressure changes, all of which affect recovery and length of hospital stay.10PubMed Central. Integrative review: postcraniotomy pain in the brain tumour patient In some patients, the surgical headache does not resolve. Persistent post-craniotomy headache can arise from several causes: nerve injury at the incision site, scar tissue attaching muscle to the membrane covering the brain, chronic inflammation, or the nervous system becoming hypersensitive to pain signals after the trauma of surgery. Risk factors for this lingering headache include surgery on the back of the skull, a history of migraine, female sex, and inadequate pain control during and immediately after the operation.11Headache Medicine. Persistent post‑craniotomy headache: a narrative review
Radiation therapy, the standard follow-up to surgery for glioblastoma, brings its own pain complications. In the short term, patients can develop scalp soreness and fatigue. The more concerning long-term risk is radiation necrosis, where healthy brain tissue near the treatment site dies months or even years after radiation. Radiation necrosis produces symptoms indistinguishable from tumor recurrence, including headache, nausea, and drowsiness, and is extremely difficult to tell apart from actual regrowth on standard imaging.12International Journal of Radiation Oncology*Biology*Physics. Critical Review Challenges With the Diagnosis and Treatment of Cerebral Radiation Necrosis For patients and families, that ambiguity is itself a source of distress: a worsening headache after treatment could mean the tumor is back, or it could mean the treatment damaged healthy tissue, and distinguishing the two often requires advanced imaging or biopsy.
How Glioblastoma Pain Is Managed
Pain control in glioblastoma involves several layers, and the specific combination shifts as the disease progresses.
Corticosteroids, especially dexamethasone, are the workhorse for managing swelling-related headache. By reducing the edema around the tumor, steroids lower intracranial pressure and can provide dramatic, rapid relief. The dilemma is that long-term steroid use carries serious side effects, including muscle wasting, immune suppression, weight gain, and mood disturbance. More troubling, a systematic review and meta-analysis found that higher doses of dexamethasone were associated with shorter survival in glioblastoma patients, with a hazard ratio of about 1.6, meaning patients on higher steroid doses had roughly 60% higher risk of death over the study period. That association held even after researchers corrected for how sick the patients already were.13PubMed Central. Dexamethasone in Patients with Glioblastoma: A Systematic Review and Meta-Analysis Whether the steroids themselves shorten survival or whether sicker patients simply need more steroids is still debated, but the finding pushes clinicians to use the lowest effective dose and taper as soon as possible.
For pain that steroids alone do not control, the approach follows the general cancer pain ladder: starting with anti-inflammatory drugs and escalating to opioids as needed. Data from the final ten days of life in a group of glioblastoma patients illustrate how heavy that reliance on medication becomes. In that study, 95% of patients were receiving opioids, 77% were on anti-inflammatory drugs, and 75% were taking anticonvulsants.14PubMed. The Last 10 Days of Patients With Glioblastoma: Assessment of Clinical Signs and Symptoms as well as Treatment These numbers reflect a disease that, by its end, demands aggressive pharmacological support for pain, seizures, and associated symptoms simultaneously.
For neuropathic pain specifically, medications like gabapentin and pregabalin are first-line options, sometimes supplemented by certain antidepressants that alter pain signaling. When those fail, as in the case of the young patient described earlier, clinicians may add opioids with stronger central nervous system activity, such as methadone. Spasticity pain can respond to muscle relaxants or, in some cases, injections of botulinum toxin directly into the overactive muscles.
Pain at the End of Life
The final weeks and months with glioblastoma bring a particular constellation of suffering that includes but extends well beyond pain. Fatigue is consistently reported as the most common symptom in the end-of-life period, followed by declining consciousness and loss of speech.15PubMed Central. Palliative care in glioblastoma patients: a systematic review Headaches, seizures, and incontinence are frequent as well. Only about one in five patients remains able to move independently by the final stage, meaning that much of the physical care falls to family or professional caregivers.
The timing of palliative care referral has been a persistent issue. Research shows that a significant share of patients with malignant brain tumors are referred to specialized palliative care within the last month of life, and one in five are not referred until the final week.15PubMed Central. Palliative care in glioblastoma patients: a systematic review Late referral means that patients may spend weeks with undertreated symptoms while still receiving aggressive treatments that are unlikely to extend survival. One review noted that chemotherapy used close to death in glioblastoma patients did not improve survival and could worsen quality of life.
When seizures become refractory in the dying phase, phenobarbital has emerged as a drug of choice, used in roughly 30% of cases in one palliative care series. Midazolam was needed in about 11% of cases to control delirium, agitation, or seizures that did not respond to other medications.16PubMed Central. Palliative care in patients with glioblastoma: A systematic review These drugs can be administered subcutaneously when patients lose the ability to swallow, which is common in the final days. The goal at that point is comfort rather than disease modification, and the sedating effects of these medications are generally considered acceptable given the severity of the symptoms they are meant to control.
The Gap Between What Patients Feel and What Caregivers Perceive
Glioblastoma erodes the very cognitive abilities a patient needs to describe their pain accurately. As the disease progresses, many patients develop aphasia, confusion, or diminished awareness, and family members or healthcare proxies must estimate how much pain the person is in. That estimation is unreliable in both directions. In a study comparing symptom reports from glioma patients and their caregivers, significant disagreement appeared across nearly every symptom category. About 22% of caregivers overestimated overall symptom severity, while 13% underestimated it. The picture was even more uneven for symptom interference, the degree to which symptoms disrupted daily life, where 32% of caregivers rated it higher than the patient did and 21% rated it lower.17PubMed Central. Self and proxy symptom reporting in glioma patient-caregiver dyads: the role of psychosocial function in rating accuracy
This disagreement is not a failure of attentiveness. Caregivers dealing with the emotional weight of watching someone decline may unconsciously project their own distress onto symptom ratings, or they may minimize symptoms as a coping mechanism. From a clinical standpoint, the finding underscores why formal pain assessment tools that use behavioral cues, like facial expression, body positioning, and vocalization, become critical once a patient can no longer self-report. Relying solely on a caregiver’s impression risks both overtreatment and undertreatment.
Cannabis and Other Non-Drug Approaches
With legalization expanding, many glioma patients have turned to cannabis products for symptom relief. The interest is real: a survey at a comprehensive cancer center confirmed that glioma patients are actively pursuing marijuana for symptom management as part of the broader national conversation around legalization.18PubMed Central. Medical Cannabis Use in Glioma Patients Treated at a Comprehensive Cancer Center in Florida However, the evidence base for cannabis specifically in brain tumor pain remains thin. Most of what we know about cannabinoids and cancer pain comes from studies in patients with other tumor types, and glioblastoma presents unique challenges: the blood-brain barrier, the cognitive effects of the disease itself, and the potential for drug interactions with anticonvulsants and corticosteroids all complicate any straightforward extrapolation.
Other non-pharmacological strategies that have some evidence in broader cancer populations include physical therapy to manage spasticity and maintain mobility, positioning techniques to reduce pressure-related discomfort, and psychological support to address the anxiety and depression that reliably amplify the experience of pain. Anxiety is particularly relevant for glioblastoma patients because the disease strips away autonomy and cognitive function at the same time it causes physical pain, creating a feedback loop where emotional distress lowers the threshold for perceiving pain, and uncontrolled pain worsens emotional distress. Addressing one without the other tends to leave patients stuck in that cycle.
For persistent post-craniotomy headache, some practitioners use nerve blocks targeted at the occipital or supraorbital nerves, especially when the headache has a clear neuropathic quality localized near the surgical scar. These are borrowed from the broader headache medicine toolkit and have not been studied extensively in the glioblastoma population specifically, but anecdotal reports and small case series suggest they can help individual patients who have not responded to standard analgesics.